Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ISIS Pharmaceuticals, Inc.    ISIS

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ISIS Pharmaceuticals, Inc. : ISIS, YHOO, MU and INTC added to Nasdaq Active Stock Watch List at EPR

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2013 | 03:05pm CEST

New York, NY -- (ACCESSWIRE) --06/25/2013-- Equity Profile Report initiates a NASDAQ Active Stock Watch List adding Isis Pharmaceuticals, Inc. (NASDAQ:ISIS), Yahoo! Inc. (NASDAQ:YHOO), Micron Technology Inc. (NASDAQ:MU) and Intel Corporation (NASDAQ:INTC)

Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) a leading company in antisense drug discovery and development finished their previous session (+29.24%) on 9,784,879 shares traded. They recently announced that the data they received from the PHASE 2 study of ISIS-APOCIIIRx in patients with high triglycerides and type 2 diabetes was very positive. They are currently us (+275.93%) from its recent 52-week low which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Isis Pharmaceuticals, Inc. (NASDAQ:ISIS)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ISIS&SubId=AW

Yahoo! Inc. (NASDAQ:YHOO) ?a company that provides search, content and communication tools via the web and mobile devices around the world finished their previous session (-4.47%) on 37,007,539. They recently announced that they have completed their acquisition of Tumblr, who are one of the fastest growing media networks in the world. This acquisition is expected to grow Yahoo?s audience by more than one billion monthly visitors. This news has prompted Equity Profile Report to add Yahoo! Inc. (NASDAQ:YHOO) to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Yahoo! Inc. (NASDAQ:YHOO)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=YHOO&SubId=AW

Also mentioned in Equity Profile Report?s Active Stock Watch List and Investor Poll was: Micron Technology Inc. (NASDAQ:MU), Intel Corporation (NASDAQ:INTC), ARM Holdings plc (NASDAQ:ARMH) and NetApp, Inc. (NASDAQ:NTAP)

To see what other investors are saying about: MU, INTC, ARMH and NTAP

Click here: http://www.equityprofilereport.com/PR.aspx?stock=MU-INTC-ARMH-NTAP&SubId=AW

EquityProfileReport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals EquityProfileReport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:http://www.EquityProfileReport.com

Disclosure: EquityProfileReport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit EquityProfileReport.com website, for complete risks and disclosures.

Contact Info:

Equity Profile Report
editor@EquityProfileReport.com


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ISIS PHARMACEUTICALS, INC.
09/26 BIOGEN : Completes Rolling Submission of New Drug Application to FDA for Nusiner..
09/23 IONIS PHARMACEUTICALS INC : Other Events (form 8-K)
09/23 INTERLEUKIN GENETICS : Cites Role in Key Antisense Drug Trial Published in The L..
09/22 IONIS PHARMACEUTICALS : Akcea Announces Publication in The Lancet of Clinical Re..
09/20 INTERCEPT PHARMACEUTICALS : Biotechnology Stocks Seeing Notable Strength In Afte..
09/17 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals to Present at Upcoming Investor Con..
09/15 ISIS PHARMACEUTICALS : Akcea Therapeutics Announces Presentations of New Data Un..
09/01 IONIS PHARMACEUTICALS' : CEO, Dr. Stanley Crooke, Receives E. B. Hershberg Award..
08/31 IONIS PHARMACEUTICALS : to Present at Upcoming Investor Conferences
08/22 ISIS PHARMACEUTICALS : Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives ..
More news
Sector news : Biotechnology & Medical Research - NEC
03:37pDJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2015 Game Plan For The Week - Cramer's Mad Money (12/18/15)
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..
2015 Isis Pharma has had enough, name changed to Ionis Pharmaceuticals
2015 Bear Afoot? No Recession Needed For A Possible Sighting
2015 PREMARKET BIOTECH DIGEST : Gilead's Upside, Shire-Baxalta Deal, ARIAD Lowers Gui..
Advertisement
Financials ($)
Sales 2016 278 M
EBIT 2016 -92,5 M
Net income 2016 -107 M
Debt 2016 47,8 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 15,9x
EV / Sales 2017 13,9x
Capitalization 4 377 M
More Financials
Chart ISIS PHARMACEUTICALS, INC.
Duration : Period :
ISIS Pharmaceuticals, Inc. Technical Analysis Chart | ISIS | US4643301090 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 14
Average target price 40,2 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Stanley T. Crooke Chairman, President & Chief Executive Officer
B. Lynne Parshall Chief Operating Officer & Director
Elizabeth L. Hougen Chief Financial Officer & SVP-Finance
C. Frank Bennett Senior Vice President-Antisense Research
Joseph H. Wender Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ISIS PHARMACEUTICALS, ..-6.12%4 377
INCYTE CORPORATION-14.06%17 522
CELLTRION, INC.--.--%11 533
LONZA GROUP AG12.32%10 064
QUINTILES TRANSNATIONA..15.89%9 472
SEATTLE GENETICS, INC.23.28%7 775
More Results